1. Immunogenicity of Biotherapy Used in Psoriasis: The Science Behind the Scenes 
Denis Jullien, Jörg C. Prinz, Frank O. Nestle 
Journal of Investigative Dermatology 
Volume 135, Issue 1, Pages (January 2015)
DOI: /jid
Copyright © 2015 The Society for Investigative Dermatology, Inc Terms and Conditions

2. Figure 1
Molecular structures of biologic drugs used to treat psoriasis. Neutralizing anti-drug antibodies (ADAs) bind to murine epitopes and idiotopes located at the antigen-binding site and prevent fixation of the therapeutic agent to its target, reducing its clinical efficacy. In contrast, ADAs that bind to allotopes and human neo-antigens at the hinge of fusion proteins are usually non-neutralizing. Both neutralizing and non-neutralizing ADAs may reduce drug efficacy through the formation of immune complexes, which may lead to increased drug clearance.
Journal of Investigative Dermatology  , 31-38DOI: ( /jid )
Copyright © 2015 The Society for Investigative Dermatology, Inc Terms and Conditions